Results 31 to 40 of about 3,081 (193)
New pieces in the BTKi resistance puzzle [PDF]
Blood, 2018 In this issue of Blood, Chen et al1 report about novel mechanisms of ibrutinib resistance related to BTK Cys481 point mutations in Waldenstrom macroglobulinemia (WM). They transfected WM and diffuse large B-cell lymphoma (DLBCL) cells with vectors containing wild-type (BTKWT) or Cys481Ser mutated (BTKCys481Ser) BTK, and examined effects of the ...
openaire +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting.
Saadia Sherazi +10 more
doaj +1 more source
, 2022 e19511 Background: Richter’s syndrome (RS) is a rare complication of chronic lymphocytic leukemia (CLL) and the median survival is generally poor. Evidence is limited regarding the biology of the disease, treatment and outcomes.
Pongas, Georgios +4 more
core +1 more source
BTK mutations in patients with chronic lymphocytic leukemia (CLL) receiving tirabrutinib
, 2023 There is now a plethora of inhibitors of Bruton’s tyrosine kinase (BTKi) in the clinic, with either covalent or non-covalent binding to BTK, for malignant and autoimmune indications.
Christopher Fegan (1725403) +10 more
core +6 more sources
EClinicalMedicine, 2023 Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies.
Pier Luigi Zinzani +20 more
doaj +1 more source
IL-4, IgM, and resistance to BTKi and PI3Kδi in CLL [PDF]
Blood, 2016 In this issue of Blood , [Aguilar-Hernandez et al][1][1][2] refine our understanding of the mechanism of action of interleukin 4 (IL-4) in promoting B-cell receptor (BCR)-mediated signaling in primary human chronic lymphocytic leukemia (CLL) and resistance to a Bruton tyrosine kinase inhibitor ...
openaire +2 more sources
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
Hemato, 2022 Waldenström Macroglobulinemia (WM) is a rare indolent lymphoma with heterogeneous clinical presentation. As there are no randomised trials suggesting the best treatment option in treatment-naive patients, guidelines suggest either rituximab-combining ...
Marina Deodato +5 more
doaj +1 more source
, 2023 IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856) +14 more
core +1 more source
Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
Annals of Translational Medicine, 2022 Bruton tyrosine kinase inhibitor (BTKi) resistance is an unsolved problem in the treatment of relapse/recurrence (R/R) mantle cell lymphoma (MCL). Although salvage therapy following ibrutinib resistance has been attempted in recent years, the survival of resistant patients was significantly reduced.
Liu, Shuozi +6 more
openaire +2 more sources
, 2023 IntroductionBruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked.
Dehui Zou (9350856) +14 more
core +1 more source